CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda

Pooled Analysis of Two Prospective Studies

Jonathan L. Chang, Sulggi A. Lee, Alexander C. Tsai, Nicholas Musinguzi, Conrad Muzoora, Bosco Bwana, Yap Boum, Jessica E. Haberer, Peter W. Hunt, Jeff Martin, David Bangsberg, Deanna L. Kroetz, Mark J. Siedner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Single-nucleotide polymorphisms (SNPs) in CYP2B6 have been shown to predict variation in plasma efavirenz concentrations, but associations between these SNPs and efavirenz-mediated depression and viral suppression are less well described. We evaluated three SNPs in CYP2B6 (rs3745274, rs28399499, and rs4803419) in Ugandan persons living with HIV. To define exposure, we used previously published pharmacokinetic modeling data to categorize participants as normal, intermediate, and poor efavirenz metabolizers. Our outcomes were probable depression in the first 2 years after antiretroviral therapy (ART) initiation (mean score of >1.75 on the Hopkins Symptom Depression Checklist) and viral suppression 6 months after ART initiation. We fit generalized estimating equation and modified Poisson regression models adjusted for demographic, clinical, and psychosocial characteristics with or without individuals with depression at the time of ART initiation. Among 242 participants, there were no differences in the pre-ART depression or viral load by efavirenz metabolism strata (p > .05). Participants were classified as normal (32%), intermediate (50%), and poor (18%) metabolizers. Seven percent (56/242) of follow-up visits met criteria for depression. Eighty-five percent (167/202) of participants who completed a 6-month visit achieved viral suppression. CYP2B6 metabolizer strata did not have a statistically significant association with either depression [adjusted risk ratio (aRR) comparing intermediate or poor vs. normal, 1.46; 95% confidence interval (CI), 0.72-2.95] or 6-month viral suppression (aRR, 1.01; 95% CI, 0.88-1.15). However, in analyses restricted to participants without pre-ART depression, poorer CYP2B6 metabolism was associated with increased odds of depression (adjusted odds ratio, 4.11; 95% CI, 1.04-16.20). Efavirenz-metabolizing allele patterns are strongly associated with risk of incident depression. Future work should elucidate further region-specific gene-environment interactions and whether alternate polymorphisms may be associated with efavirenz metabolism.

Original languageEnglish (US)
Pages (from-to)982-992
Number of pages11
JournalAIDS Research and Human Retroviruses
Volume34
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

efavirenz
Uganda
Genetic Polymorphisms
HIV
Prospective Studies
Single Nucleotide Polymorphism
Odds Ratio
Confidence Intervals
Therapeutics
Gene-Environment Interaction
Viral Load
Checklist
Cytochrome P-450 CYP2B6
Pharmacokinetics
Alleles
Demography

Keywords

  • CYP2B6
  • depression
  • efavirenz
  • HIV
  • single-nucleotide polymorphisms
  • viral suppression

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda : Pooled Analysis of Two Prospective Studies. / Chang, Jonathan L.; Lee, Sulggi A.; Tsai, Alexander C.; Musinguzi, Nicholas; Muzoora, Conrad; Bwana, Bosco; Boum, Yap; Haberer, Jessica E.; Hunt, Peter W.; Martin, Jeff; Bangsberg, David; Kroetz, Deanna L.; Siedner, Mark J.

In: AIDS Research and Human Retroviruses, Vol. 34, No. 11, 01.11.2018, p. 982-992.

Research output: Contribution to journalArticle

Chang, Jonathan L. ; Lee, Sulggi A. ; Tsai, Alexander C. ; Musinguzi, Nicholas ; Muzoora, Conrad ; Bwana, Bosco ; Boum, Yap ; Haberer, Jessica E. ; Hunt, Peter W. ; Martin, Jeff ; Bangsberg, David ; Kroetz, Deanna L. ; Siedner, Mark J. / CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda : Pooled Analysis of Two Prospective Studies. In: AIDS Research and Human Retroviruses. 2018 ; Vol. 34, No. 11. pp. 982-992.
@article{cca894e482b74a75811bb891672a0541,
title = "CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies",
abstract = "Single-nucleotide polymorphisms (SNPs) in CYP2B6 have been shown to predict variation in plasma efavirenz concentrations, but associations between these SNPs and efavirenz-mediated depression and viral suppression are less well described. We evaluated three SNPs in CYP2B6 (rs3745274, rs28399499, and rs4803419) in Ugandan persons living with HIV. To define exposure, we used previously published pharmacokinetic modeling data to categorize participants as normal, intermediate, and poor efavirenz metabolizers. Our outcomes were probable depression in the first 2 years after antiretroviral therapy (ART) initiation (mean score of >1.75 on the Hopkins Symptom Depression Checklist) and viral suppression 6 months after ART initiation. We fit generalized estimating equation and modified Poisson regression models adjusted for demographic, clinical, and psychosocial characteristics with or without individuals with depression at the time of ART initiation. Among 242 participants, there were no differences in the pre-ART depression or viral load by efavirenz metabolism strata (p > .05). Participants were classified as normal (32{\%}), intermediate (50{\%}), and poor (18{\%}) metabolizers. Seven percent (56/242) of follow-up visits met criteria for depression. Eighty-five percent (167/202) of participants who completed a 6-month visit achieved viral suppression. CYP2B6 metabolizer strata did not have a statistically significant association with either depression [adjusted risk ratio (aRR) comparing intermediate or poor vs. normal, 1.46; 95{\%} confidence interval (CI), 0.72-2.95] or 6-month viral suppression (aRR, 1.01; 95{\%} CI, 0.88-1.15). However, in analyses restricted to participants without pre-ART depression, poorer CYP2B6 metabolism was associated with increased odds of depression (adjusted odds ratio, 4.11; 95{\%} CI, 1.04-16.20). Efavirenz-metabolizing allele patterns are strongly associated with risk of incident depression. Future work should elucidate further region-specific gene-environment interactions and whether alternate polymorphisms may be associated with efavirenz metabolism.",
keywords = "CYP2B6, depression, efavirenz, HIV, single-nucleotide polymorphisms, viral suppression",
author = "Chang, {Jonathan L.} and Lee, {Sulggi A.} and Tsai, {Alexander C.} and Nicholas Musinguzi and Conrad Muzoora and Bosco Bwana and Yap Boum and Haberer, {Jessica E.} and Hunt, {Peter W.} and Jeff Martin and David Bangsberg and Kroetz, {Deanna L.} and Siedner, {Mark J.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1089/aid.2018.0062",
language = "English (US)",
volume = "34",
pages = "982--992",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda

T2 - Pooled Analysis of Two Prospective Studies

AU - Chang, Jonathan L.

AU - Lee, Sulggi A.

AU - Tsai, Alexander C.

AU - Musinguzi, Nicholas

AU - Muzoora, Conrad

AU - Bwana, Bosco

AU - Boum, Yap

AU - Haberer, Jessica E.

AU - Hunt, Peter W.

AU - Martin, Jeff

AU - Bangsberg, David

AU - Kroetz, Deanna L.

AU - Siedner, Mark J.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Single-nucleotide polymorphisms (SNPs) in CYP2B6 have been shown to predict variation in plasma efavirenz concentrations, but associations between these SNPs and efavirenz-mediated depression and viral suppression are less well described. We evaluated three SNPs in CYP2B6 (rs3745274, rs28399499, and rs4803419) in Ugandan persons living with HIV. To define exposure, we used previously published pharmacokinetic modeling data to categorize participants as normal, intermediate, and poor efavirenz metabolizers. Our outcomes were probable depression in the first 2 years after antiretroviral therapy (ART) initiation (mean score of >1.75 on the Hopkins Symptom Depression Checklist) and viral suppression 6 months after ART initiation. We fit generalized estimating equation and modified Poisson regression models adjusted for demographic, clinical, and psychosocial characteristics with or without individuals with depression at the time of ART initiation. Among 242 participants, there were no differences in the pre-ART depression or viral load by efavirenz metabolism strata (p > .05). Participants were classified as normal (32%), intermediate (50%), and poor (18%) metabolizers. Seven percent (56/242) of follow-up visits met criteria for depression. Eighty-five percent (167/202) of participants who completed a 6-month visit achieved viral suppression. CYP2B6 metabolizer strata did not have a statistically significant association with either depression [adjusted risk ratio (aRR) comparing intermediate or poor vs. normal, 1.46; 95% confidence interval (CI), 0.72-2.95] or 6-month viral suppression (aRR, 1.01; 95% CI, 0.88-1.15). However, in analyses restricted to participants without pre-ART depression, poorer CYP2B6 metabolism was associated with increased odds of depression (adjusted odds ratio, 4.11; 95% CI, 1.04-16.20). Efavirenz-metabolizing allele patterns are strongly associated with risk of incident depression. Future work should elucidate further region-specific gene-environment interactions and whether alternate polymorphisms may be associated with efavirenz metabolism.

AB - Single-nucleotide polymorphisms (SNPs) in CYP2B6 have been shown to predict variation in plasma efavirenz concentrations, but associations between these SNPs and efavirenz-mediated depression and viral suppression are less well described. We evaluated three SNPs in CYP2B6 (rs3745274, rs28399499, and rs4803419) in Ugandan persons living with HIV. To define exposure, we used previously published pharmacokinetic modeling data to categorize participants as normal, intermediate, and poor efavirenz metabolizers. Our outcomes were probable depression in the first 2 years after antiretroviral therapy (ART) initiation (mean score of >1.75 on the Hopkins Symptom Depression Checklist) and viral suppression 6 months after ART initiation. We fit generalized estimating equation and modified Poisson regression models adjusted for demographic, clinical, and psychosocial characteristics with or without individuals with depression at the time of ART initiation. Among 242 participants, there were no differences in the pre-ART depression or viral load by efavirenz metabolism strata (p > .05). Participants were classified as normal (32%), intermediate (50%), and poor (18%) metabolizers. Seven percent (56/242) of follow-up visits met criteria for depression. Eighty-five percent (167/202) of participants who completed a 6-month visit achieved viral suppression. CYP2B6 metabolizer strata did not have a statistically significant association with either depression [adjusted risk ratio (aRR) comparing intermediate or poor vs. normal, 1.46; 95% confidence interval (CI), 0.72-2.95] or 6-month viral suppression (aRR, 1.01; 95% CI, 0.88-1.15). However, in analyses restricted to participants without pre-ART depression, poorer CYP2B6 metabolism was associated with increased odds of depression (adjusted odds ratio, 4.11; 95% CI, 1.04-16.20). Efavirenz-metabolizing allele patterns are strongly associated with risk of incident depression. Future work should elucidate further region-specific gene-environment interactions and whether alternate polymorphisms may be associated with efavirenz metabolism.

KW - CYP2B6

KW - depression

KW - efavirenz

KW - HIV

KW - single-nucleotide polymorphisms

KW - viral suppression

UR - http://www.scopus.com/inward/record.url?scp=85056024433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056024433&partnerID=8YFLogxK

U2 - 10.1089/aid.2018.0062

DO - 10.1089/aid.2018.0062

M3 - Article

VL - 34

SP - 982

EP - 992

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 11

ER -